SG11202108303SA - Inhibition of unintended mutations in gene editing - Google Patents

Inhibition of unintended mutations in gene editing

Info

Publication number
SG11202108303SA
SG11202108303SA SG11202108303SA SG11202108303SA SG11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA
Authority
SG
Singapore
Prior art keywords
inhibition
gene editing
unintended mutations
unintended
mutations
Prior art date
Application number
SG11202108303SA
Other languages
English (en)
Inventor
Jia Chen
Bei Yang
Li Yang
Xingxu Huang
Lijie Wang
Original Assignee
Univ Shanghai Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Shanghai Technology filed Critical Univ Shanghai Technology
Publication of SG11202108303SA publication Critical patent/SG11202108303SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21111—Aqualysin 1 (3.4.21.111)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22044—Nuclear-inclusion-a endopeptidase (3.4.22.44)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202108303SA 2019-02-02 2020-02-03 Inhibition of unintended mutations in gene editing SG11202108303SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019074577 2019-02-02
PCT/CN2020/074218 WO2020156575A1 (en) 2019-02-02 2020-02-03 Inhibition of unintended mutations in gene editing

Publications (1)

Publication Number Publication Date
SG11202108303SA true SG11202108303SA (en) 2021-08-30

Family

ID=71841894

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108303SA SG11202108303SA (en) 2019-02-02 2020-02-03 Inhibition of unintended mutations in gene editing

Country Status (12)

Country Link
US (3) US11384353B2 (ko)
EP (1) EP3918083A4 (ko)
JP (2) JP7518549B2 (ko)
KR (1) KR20210126042A (ko)
CN (4) CN113661248B (ko)
AU (2) AU2020214090B2 (ko)
BR (1) BR112021015092A2 (ko)
CA (1) CA3128283A1 (ko)
IL (1) IL285194A (ko)
SG (1) SG11202108303SA (ko)
WO (1) WO2020156575A1 (ko)
ZA (2) ZA202105895B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117120621A (zh) * 2020-11-12 2023-11-24 上海科技大学 提高效率和准确性的基因组编辑
CN112575014B (zh) * 2020-12-11 2022-04-01 安徽省农业科学院水稻研究所 一种碱基编辑器SpCas9-LjCDAL1及其构建和应用
BR112023019773A2 (pt) * 2021-04-02 2024-03-12 Univ Shanghai Technology Método para promover a produção de gama-globina em uma célula humana, polinucleotídeos codificando uma proteína associada a um crispr (cas), uma nucleobase desaminase, um rna de guia único (sgrna) e um rna de guia único auxiliar (hsgrna), e, proteína de fusão
CN118556122A (zh) * 2021-11-18 2024-08-27 正序(上海)生物科技有限公司 表面抗原阴性细胞的再生
AU2023218196A1 (en) * 2022-02-08 2024-08-22 Toolgen Incorporated Method for predicting off-target which can occur in process of editing genome by using prime editing system
WO2024012435A1 (en) 2022-07-11 2024-01-18 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hereditary angioedema
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
WO2024088401A1 (en) * 2022-10-28 2024-05-02 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for reducing immunogenicity and graft versus host response
WO2024095245A2 (en) 2022-11-04 2024-05-10 LifeEDIT Therapeutics, Inc. Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
WO2024109745A1 (en) * 2022-11-21 2024-05-30 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hbv infection
US20240344087A1 (en) * 2022-11-23 2024-10-17 Amber Bio Inc. Gene-modifying endonucleases
WO2024127370A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use
WO2024127369A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
CN117092084B (zh) * 2023-10-20 2024-01-12 浙江迪福润丝生物科技有限公司 Wnv蛋白酶抑制剂的筛选方法和抑制效果评价方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6445314A (en) * 1987-04-16 1989-02-17 Res Corp Technologies Inc Antitumoral
US8288094B2 (en) * 2008-04-09 2012-10-16 Institut Pasteur APOBEC3 mediated DNA editing
US11053481B2 (en) * 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
CN105886498A (zh) 2015-05-13 2016-08-24 沈志荣 CRISPR-Cas9特异性敲除人PCSK9基因的方法以及用于特异性靶向PCSK9基因的sgRNA
IL294014B2 (en) * 2015-10-23 2024-07-01 Harvard College Nucleobase editors and their uses
EP3530737A4 (en) * 2016-09-13 2020-04-29 Toolgen Incorporated METHOD FOR IDENTIFYING DNA BASE EDITING USING CYTOSINE DEAMINASE
US11192929B2 (en) * 2016-12-08 2021-12-07 Regents Of The University Of Minnesota Site-specific DNA base editing using modified APOBEC enzymes
CN108342387B (zh) * 2017-01-24 2021-09-24 谭旭 Pcsk9抑制剂类降血脂药的递送系统和生物制剂
CA3062595A1 (en) * 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
AU2018273968A1 (en) * 2017-05-25 2019-11-28 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
CN109136272A (zh) * 2017-06-15 2019-01-04 中山大学 用于特异性修复人hbb基因突变的碱基编辑系统、方法、试剂盒及其在人生殖系中的应用
CN109021111B (zh) * 2018-02-23 2021-12-07 上海科技大学 一种基因碱基编辑器

Also Published As

Publication number Publication date
EP3918083A1 (en) 2021-12-08
EP3918083A4 (en) 2023-03-29
JP7518549B2 (ja) 2024-07-18
KR20210126042A (ko) 2021-10-19
IL285194A (en) 2021-09-30
US20240026342A1 (en) 2024-01-25
ZA202212490B (en) 2024-09-25
JP2024109660A (ja) 2024-08-14
CN116656676A (zh) 2023-08-29
CN113661248B (zh) 2022-09-16
ZA202105895B (en) 2024-07-31
AU2020214090B2 (en) 2022-09-15
CN116355966A (zh) 2023-06-30
US20220064626A1 (en) 2022-03-03
CN113661248A (zh) 2021-11-16
US11384353B2 (en) 2022-07-12
AU2020214090A1 (en) 2021-09-16
US20230094769A1 (en) 2023-03-30
JP2022526695A (ja) 2022-05-26
AU2022287550A1 (en) 2023-02-02
CA3128283A1 (en) 2020-08-06
CN116286802A (zh) 2023-06-23
US11840685B2 (en) 2023-12-12
WO2020156575A1 (en) 2020-08-06
BR112021015092A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
IL285194A (en) Inhibition of unintended mutations in gene editing
GB2587970B (en) Compositions and methods for gene editing
IL267500A (en) Genomic editing of pcks9
HK1252469A1 (zh) 深內含子突變的基因編輯
IL284400A (en) Polypeptides useful for gene editing and methods of use
IL270963A (en) Gene therapy combining a viral vector and genome editing for gene therapy of genetic diseases
EP3362104A4 (en) METHODS AND COMPOSITIONS USING CPF1 FOR RNA-GUIDED GENETIC EDITION
EP3487523A4 (en) THERAPEUTIC APPLICATIONS OF THE CPF1-BASED GENOME EDITION
IL271232A (en) Compounds and methods for editing the genome
EP3356529A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING LPA GENE EXPRESSION
IL281109A (en) Preparations and methods for improving nuclease- and triplex-based gene editing
IL274351A (en) Primary cellular gene editing
EP3820503A4 (en) METHODS OF ACHIEVING HIGH SPECIFICITY OF GENOMIC EDITING
EP3781677A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
EP3801574A4 (en) METHODS OF GENOME EDITING AND ACTIVATION OF CELLS
EP3781683A4 (en) METHODS AND COMPOSITIONS FOR GENOME EDITING
EP3796894A4 (en) METHODS AND COMPOSITIONS FOR GENOME EDITING
EP3723733A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER WITH EXOSOME-ASSOCIATED GENE EDITING
EP3509606A4 (en) PRIMARY B LYMPHOCYTE RESULTING FROM GENE EDITING AND METHODS OF PREPARATION AND USE
EP3772905A4 (en) FAD2 GENES AND MUTATIONS
EP3987024A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING
EP3615674A4 (en) METHOD OF TREATMENT OF RHEUMATOID ARTHRITIS USING RNA-GUIDED GENOME EDITING OF THE HLA GENE
IL282608A (en) Preparations and methods for NHEJ-mediated genome editing
SG10201906239RA (en) Compositions and methods for inhibition of rna editing for treatment of cancer
IL309809A (en) Genomic editing of RBM20 mutations